Business & Industry
UCB Acquires Candid Therapeutics in a $2 Billion-Plus Deal to Strengthen Immunology Pipeline
Belgian pharmaceutical company UCB is making a substantial move to expand its immunology pipeline, entering into a multi-billion dollar agreement to acquire Candid Therapeutics a clinical-stage biotechnology company working on therapies designed to treat autoimmune disorders by resetting the...
Business & Industry
BeOne Signs $2B Trispecific Antibody Deal with Huahui Health
BeOne Medicines has entered into a high-value agreement with Huahui Health, committing $20 million upfront to secure an exclusive option for a preclinical trispecific antibody candidate developed by the Chinese biotech firm. The asset, identified as HH160, targets PD-1,...
News
Glass vs Polymer: Choosing the Right Material for Parenteral Packaging
In the pharmaceutical industry, material selection plays a critical role in ensuring the safety, stability, and efficacy of injectable drugs. Parenteral products those administered via injection, infusion, or implantation require highly specialized packaging to maintain sterility and prevent contamination....
Business & Industry
FDA Advances Real-Time Clinical Trials With AstraZeneca, Amgen
The U.S. Food and Drug Administration has unveiled a new regulatory initiative to enable real-time clinical trials, marking a structural shift in how drug development data is reviewed. The program, already supported by AstraZeneca and Amgen, introduces a model...
Business & Industry
Chiesi Advances Rare Disease Portfolio with KalVista Deal
Chiesi Group has entered into a definitive agreement to acquire KalVista Pharmaceuticals, marking a significant step in strengthening its rare disease portfolio. Announced on 29 April 2026, the transaction will see Chiesi acquire all outstanding shares of KalVista for...
Business & Industry
AstraZeneca UK Investment Resumes with £300m Commitment
In a reversal of its earlier stance, AstraZeneca has confirmed a £300m commitment to the UK, marking a renewed push into domestic operations after previously halting major projects. The announcement, delivered in Parliament by Keir Starmer, signals a shift...
News
The Science of Regeneration: A Comprehensive Guide to GHK-Cu Peptide
The landscape of regenerative medicine has shifted significantly toward signaling molecules that can modulate gene expression. Among the most researched and versatile of these molecules is the GHK-Cu peptide, a naturally occurring copper complex first identified in human plasma.
As...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read